Ticker LaunchReverse merger · Completed · RNAC
Cartesian Therapeutics, Inc.
Reverse merger with Selecta Biosciences, Inc. (SELB)
Cartesian Therapeutics, Inc. merged into Selecta Biosciences, Inc. (SELB), a clinical-stage biotech (immune tolerance platform), in a reverse merger that takes the private company public. The deal was announced on Apr 4, 2023 and closed on Nov 13, 2023. The combined company trades as Cartesian Therapeutics, Inc. (RNAC) on Nasdaq.
Cartesian Therapeutics, Inc. develops RNA cell therapies, including mRNA-engineered cell therapy candidates for autoimmune disease. It was formed when Selecta Biosciences merged with the privately held Cartesian.
- Status
- Completed
- Private company
- Cartesian Therapeutics, Inc.
- Public company
- Selecta Biosciences, Inc. (SELB)
- Public company business before
- clinical-stage biotech (immune tolerance platform)
- Announced
- Apr 4, 2023
- Closed
- Nov 13, 2023
- Combined company
- Cartesian Therapeutics, Inc. (RNAC)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Announcement 8-K Apr 4, 2023
- Closing 8-K Nov 13, 2023
- Closing press release
- All filings on EDGAR CIK 1453687
Other completed reverse mergers
- Neurogene Inc.into Neoleukin Therapeutics, Inc. · Dec 19, 2023
- Two Trees Beverage Companyinto MDwerks, Inc. · Dec 8, 2023
- Korro Bio, Inc.into Frequency Therapeutics, Inc. · Nov 3, 2023
- Beijing Continent Pharmaceuticals Co., Ltd. (via GNI Group)into Catalyst Biosciences, Inc. · Oct 30, 2023
- Tourmaline Bio, Inc.into Talaris Therapeutics, Inc. · Oct 19, 2023
- Notable Labs, Inc.into Vascular Biogenics Ltd. · Oct 16, 2023